Armis Advisers’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.74M Buy
4,010
+480
+14% +$566K 0.4% 40
2026
Q2
$4.24M Buy
3,530
+93
+3% +$95K 0.39% 43
2026
Q1
$3.49M Buy
3,437
+387
+13% +$392K 0.34% 51
2025
Q4
$2.77M Buy
3,050
+139
+5% +$133K 0.31% 57
2025
Q3
$2.54M Buy
2,911
+241
+9% +$179K 0.23% 68
2025
Q2
$2.11M Buy
2,670
+425
+19% +$330K 0.17% 111
2025
Q1
$1.95M Buy
2,245
+1,490
+197% +$1.24M 0.18% 105
2024
Q4
$583K Buy
+755
New +$625K 0.07% 175

Other funds holding LLY

Armis Advisers's LLY Position: Q3 2026 in Review

Armis Advisers increased its Eli Lilly (LLY) stake by 14% in Q3 2026, buying an estimated $566K and bringing the position to 4,010 shares worth $4.74M. The position accounts for 0.4% of the portfolio, ranked #40.

Armis Advisers first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. 1,223 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Armis Advisers held 4,010 shares of Eli Lilly worth $4.74M as of Q3 2026.
  • Armis Advisers bought 480 Eli Lilly shares in Q3 2026, an estimated $566K.
  • Eli Lilly made up 0.4% of Armis Advisers's portfolio in Q3 2026, its #40 holding.
  • Armis Advisers first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • 1,223 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Armis Advisers's 13F filing for Q3 2026, filed 13 Oct 2026.